Agios Pharmaceuticals Inc (AGIO)
55.54
+0.92
(+1.68%)
USD |
NASDAQ |
Nov 21, 16:00
55.55
+0.01
(+0.02%)
After-Hours: 20:00
Agios Pharmaceuticals Enterprise Value: 2.163B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.163B |
| November 20, 2024 | 2.110B |
| November 19, 2024 | 2.098B |
| November 18, 2024 | 2.012B |
| November 15, 2024 | 2.062B |
| November 14, 2024 | 2.155B |
| November 13, 2024 | 2.337B |
| November 12, 2024 | 2.361B |
| November 11, 2024 | 2.443B |
| November 08, 2024 | 2.363B |
| November 07, 2024 | 2.136B |
| November 06, 2024 | 1.937B |
| November 05, 2024 | 1.659B |
| November 04, 2024 | 1.552B |
| November 01, 2024 | 1.554B |
| October 31, 2024 | 1.529B |
| October 30, 2024 | 1.636B |
| October 29, 2024 | 1.666B |
| October 28, 2024 | 1.623B |
| October 25, 2024 | 1.567B |
| October 24, 2024 | 1.566B |
| October 23, 2024 | 1.523B |
| October 22, 2024 | 1.583B |
| October 21, 2024 | 1.599B |
| October 18, 2024 | 1.590B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.512B |
| October 16, 2024 | 1.487B |
| October 15, 2024 | 1.392B |
| October 14, 2024 | 1.349B |
| October 11, 2024 | 1.427B |
| October 10, 2024 | 1.380B |
| October 09, 2024 | 1.327B |
| October 08, 2024 | 1.305B |
| October 07, 2024 | 1.310B |
| October 04, 2024 | 1.352B |
| October 03, 2024 | 1.308B |
| October 02, 2024 | 1.378B |
| October 01, 2024 | 1.417B |
| September 30, 2024 | 1.529B |
| September 27, 2024 | 2.025B |
| September 26, 2024 | 2.164B |
| September 25, 2024 | 2.220B |
| September 24, 2024 | 2.081B |
| September 23, 2024 | 2.034B |
| September 20, 2024 | 2.078B |
| September 19, 2024 | 2.126B |
| September 18, 2024 | 2.021B |
| September 17, 2024 | 2.030B |
| September 16, 2024 | 2.014B |
| September 13, 2024 | 2.086B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.17M
Minimum
Jun 14 2022
3.415B
Maximum
Feb 11 2021
1.359B
Average
1.045B
Median
Sep 15 2021
Enterprise Value Benchmarks
| Pfizer Inc | 199.35B |
| Regeneron Pharmaceuticals Inc | 74.00B |
| Ligand Pharmaceuticals Inc | 1.983B |
| ADMA Biologics Inc | 5.050B |
| AnaptysBio Inc | 214.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 947.92M |
| Revenue (Quarterly) | 8.964M |
| Total Expenses (Quarterly) | 111.78M |
| EPS Diluted (Quarterly) | 16.22 |
| Gross Profit Margin (Quarterly) | 91.27% |
| Earnings Yield | 20.45% |
| Normalized Earnings Yield | -11.33 |